Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Erythromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.86 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.86 |
| ▸ | TSHR | P16473 | 2/20 | 0.86 |
| ▸ | LMNA | P02545 | 2/20 | 0.86 |
| ▸ | MLNR | O43193 | 2/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.86 |
| ▸ | ALB | P02768 | 1/20 | 0.86 |
| ▸ | CNR1 | P21554 | 1/20 | 0.86 |
| ▸ | HTR2A | P28223 | 1/20 | 0.86 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.86 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.86 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.82 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.82 |
| ▸ | SLCO1B3 | Q9NPD5 | 3/20 | 0.80 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.80 |
| ▸ | AR | P10275 | 1/20 | 0.80 |
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythromycin SCHEMBL11340609 | 1.00 | CYP3A4 (0.86) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL11340606 | 1.00 | CYP3A4 (0.86) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL29116300 | 1.00 | CYP3A4 (0.86) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL40641 | 1.00 | CYP3A4 (0.86) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL10899622 | 0.99 | CYP3A4 (0.84) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL10899617 | 0.99 | CYP3A4 (0.84) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL7056963 | 0.95 | CYP3A4 (0.93) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL7056958 | 0.95 | CYP3A4 (0.93) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL10897935 | 0.94 | CYP3A4 (0.83) | CYP3A4KCNH2ABCB1TSHRLMNA | |
| Erythromycin SCHEMBL9487690 | 0.94 | CYP3A4 (0.94) | CYP3A4KCNH2ABCB1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020263729-A1 | METHOD AND FORMULATION FOR TREATMENT OF WOUNDS BY NEW TISSUE REGENERATION WITH REDUCED TRAUMA AND SCAR TISSUE FORMATION | GALLINA CHARLES (US) | 2020-12-30 | — | — | WO | claimed |
| US-20200397720-A1 | METHOD AND FORMULATION FOR TREATMENT OF WOUNDS BY NEW TISSUE REGENERATION WITH REDUCED TRAUMA AND SCAR TISSUE FORMATION | GALLINA CHARLES HUNTINGTON (US) | 2020-12-24 | — | — | US | claimed |
| US-9227999-B2 | Antimicrobial cationic peptides and formulations thereof | CARRUS CAPITAL CORPORATION (CA) | 2016-01-05 | — | — | US | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | claimed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
| EP-4665724-A1 | TYPE II TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | Ohio State Innovation Foundation (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-3866826-B1 | ANTIMICROBIAL PEPTIDES AND METHODS OF USING THE SAME | RIPTIDE BIOSCIENCE INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12352749-B2 | Human Streptococcus pneumoniae antibodies and uses therefor | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250213497-A1 | A NANO IN MICRO FORMULATION AND PROCESS THEREOF | AMRITA VISHWA VIDYAPEETHAM (IN) | 2025-07-03 | — | — | US | disclosed |
| WO-2024173781-A1 | TYPE II TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024163315-A2 | DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS | DEVORE DALE (US) | 2024-08-08 | — | — | WO | disclosed |
| EP-1174439-A2 | Compositions and methods for treating infections using analogues of indolicidin | Micrologix Biotech, Inc. (CA) | 2002-01-23 | — | — | EP | disclosed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | disclosed |
| US-6180604-B1 | Compositions and methods for treating infections using analogues of indolicidin | MICROLOGIX BIOTECH INC. (CA) | 2001-01-30 | — | — | US | disclosed |
| EP-0966481-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | Micrologix Biotech, Inc. (CA) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999065506-A2 | CANCER THERAPY WITH INDOLICIDIN OR CATIONIC PEPTIDES AND THEIR POLYMER CONJUGATES | MICROLOGIX BIOTECH INC. (CA) | 1999-12-23 | — | — | WO | disclosed |
| WO-1998040401-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | MICROLOGIX BIOTECH INC. (CA) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | CYP3A4 758/4885KCNH2 3557/4885ABCB1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.